Drug facts
MoleculeBupropion (Wellbutrin XL)
Generics already compete: 27 makers on the market. 81 A-rated products from 27 makers substitute at the counter.
Wellbutrin was first approved by the FDA on 12/30/1985 under NDA 018644; the application holder is Glaxosmithkline. The Orange Book lists NDA 018644 as discontinued.
The latest NADAC for BUPROPION HCL 75 MG TABLET is $0.10 per unit (as of 10/28/2026).
Holder GlaxosmithklineApplication NDA 018644Approved 12/30/1985
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Wellbutrin patent listed in the Orange Book Orange Book
- Later patents, other products
- Forfivo XL 08/23/2028 Orange Book
02Competition
- Generics
- 27 generic makers Orange Book
- First generic approved
- 11/29/1999 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Bupropion profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.10 per unitBUPROPION HCL 75 MG TABLET, as of 10/28/2026 CMS NADAC
- Latest recall
- 09/15/2025Class II, Bupropion Hydrochloride Extended-Release..., Graviti Pharmaceuticals Private Limited FDA enforcement
04Product
- Application holder
- Glaxosmithkline Orange Book
- Application
- NDA 018644 Orange Book
- First approved
- 12/30/1985 Orange Book
- Dosage forms
- tablet; tablet, extended release
- Routes
- oral
- Other brand names
- Forfivo XLWellbutrin SR
- Status
- NDA 018644 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.